Page last updated: 2024-08-18

quinuclidines and salmeterol xinafoate

quinuclidines has been researched along with salmeterol xinafoate in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Banerji, D; Bateman, ED; Mahler, DA; Patalano, F; Vogelmeier, CF; Wedzicha, JA	1
Bjermer, L; Boucot, IH; Compton, C; Jones, PW; Kerwin, EM; Lipson, DA; Maltais, F; Naya, IP; Tombs, L; Vahdati-Bolouri, M; Vogelmeier, CF; Watkins, ML	1
Bjermer, L; Boucot, I; Compton, C; Ismaila, AS; Jones, PW; Kendall, R; Kerwin, E; Lipson, DA; Maltais, F; Martin, A; Risebrough, NA; Shah, D; Shukla, S; Tombs, L; Vogelmeier, CF	1
Agarwal, J; Compton, C; Czira, A; Dong, X; Duarte, M; Haeussler, K; Halpin, DMG; Ismaila, AS; Malmenäs, M; Nassim, M; Shen, Y; Tongbram, V; Vogelmeier, CF; Živković-Gojović, M	1

Reviews

2 review(s) available for quinuclidines and salmeterol xinafoate

Article	Year
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert review of respiratory medicine, 2014, Volume: 8, Issue:3 Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Management; Disease Progression; Drug Combinations; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome	2014
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis. Advances in therapy, 2022, Volume: 39, Issue:11 Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Dyspnea; Forced Expiratory Volume; Glycopyrrolate; Humans; Muscarinic Antagonists; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome	2022

Article

Year

Recent advances in COPD disease management with fixed-dose long-acting combination therapies.

Expert review of respiratory medicine, 2014, Volume: 8, Issue:3

Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Management; Disease Progression; Drug Combinations; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome

2014

Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.

Advances in therapy, 2022, Volume: 39, Issue:11

Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Dyspnea; Forced Expiratory Volume; Glycopyrrolate; Humans; Muscarinic Antagonists; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome

2022

Trials

1 trial(s) available for quinuclidines and salmeterol xinafoate

Article	Year
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respiratory research, 2019, Oct-30, Volume: 20, Issue:1 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Treatment Outcome	2019

Article

Year

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.

Respiratory research, 2019, Oct-30, Volume: 20, Issue:1

Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Treatment Outcome

2019

Other Studies

1 other study(ies) available for quinuclidines and salmeterol xinafoate

Article	Year
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International journal of chronic obstructive pulmonary disease, 2021, Volume: 16 Topics: Administration, Inhalation; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cost-Benefit Analysis; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Treatment Outcome; United Kingdom	2021

Article

Year

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.

International journal of chronic obstructive pulmonary disease, 2021, Volume: 16

Topics: Administration, Inhalation; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cost-Benefit Analysis; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Treatment Outcome; United Kingdom

2021